Imaging pathological tau in atypical parkinsonisms: A review
Atypical parkinsonisms (APs) are a group of diseases linked to tau pathology. These include progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). In the initial stages, these APs may have similar clinical manifestations to Parkinson’s disease (PD) and other parkinsonisms: bradyki...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Clinical Parkinsonism & Related Disorders |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112522000263 |
| _version_ | 1817971389196402688 |
|---|---|
| author | Anastassia M. Mena Antonio P. Strafella |
| author_facet | Anastassia M. Mena Antonio P. Strafella |
| author_sort | Anastassia M. Mena |
| collection | DOAJ |
| description | Atypical parkinsonisms (APs) are a group of diseases linked to tau pathology. These include progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). In the initial stages, these APs may have similar clinical manifestations to Parkinson’s disease (PD) and other parkinsonisms: bradykinesia, postural instability, tremor, and cognitive decline. Because of this, one major hurdle is the accurate early diagnosis of APs. Recent advances in positron emission tomography (PET) radiotracer development have allowed for targeting pathological tau in Alzheimer’s disease (AD). Currently, work is still in progress for identifying a first-in-class radiotracer for imaging tau in APs. In this review, we evaluate the literature on in vitro and in vivo testing of current tau PET radiotracers in APs. The tau PET tracers assessed include both first-generation tracers ([18F]AV-1451, [18F]FDDNP, [18F]THK derivatives, and [11C]PBB3) and second-generation tracers ([18F]PM-PBB3, [18F]PI-2620, [18F]RO-948, [18F]JNJ-067, [18F]MK-6240, and [18F]CBD-2115). Concerns regarding off-target binding to cerebral white matter and the basal ganglia are still prominent with first-generation tracers, but this seems to have been mediated in a handful of second-generation tracers, including [18F]PI-2620 and [18F]PM-PBB3. Additionally, these two tracers and [18F]MK-6240 show promising results for imaging PSP- and CBD-tau. Overall, [18F]AV-1451 is the most widely studied tracer but the mixed results regarding its efficacy for use in imaging AP-tau is a cause for concern moving forward. Instead, future work may benefit from focusing on the second-generation radiotracers which seem to have a higher specificity for AP-tau than those originally developed for imaging AD-tau. |
| first_indexed | 2024-04-13T20:46:11Z |
| format | Article |
| id | doaj.art-7520737892ea49baa07bc14b04973892 |
| institution | Directory Open Access Journal |
| issn | 2590-1125 |
| language | English |
| last_indexed | 2024-04-13T20:46:11Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Parkinsonism & Related Disorders |
| spelling | doaj.art-7520737892ea49baa07bc14b049738922022-12-22T02:30:41ZengElsevierClinical Parkinsonism & Related Disorders2590-11252022-01-017100155Imaging pathological tau in atypical parkinsonisms: A reviewAnastassia M. Mena0Antonio P. Strafella1Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Ontario, Canada; Corresponding authors at: Toronto Western Hospital and Research Institute, Brain Health Imaging Centre, CAMH, University of Toronto, Toronto, ON, Canada.Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada; Division of Brain, Imaging and Behaviour – Systems Neuroscience, Krembil Brain Institute, UHN, University of Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Ontario, Canada; Edmond J. Safra Parkinson Disease Program & Morton and Gloria Shulman Movement Disorder Unit, Neurology Division, Dept. of Medicine, Toronto Western Hospital, UHN, University of Toronto, Ontario, Canada; Corresponding authors at: Toronto Western Hospital and Research Institute, Brain Health Imaging Centre, CAMH, University of Toronto, Toronto, ON, Canada.Atypical parkinsonisms (APs) are a group of diseases linked to tau pathology. These include progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). In the initial stages, these APs may have similar clinical manifestations to Parkinson’s disease (PD) and other parkinsonisms: bradykinesia, postural instability, tremor, and cognitive decline. Because of this, one major hurdle is the accurate early diagnosis of APs. Recent advances in positron emission tomography (PET) radiotracer development have allowed for targeting pathological tau in Alzheimer’s disease (AD). Currently, work is still in progress for identifying a first-in-class radiotracer for imaging tau in APs. In this review, we evaluate the literature on in vitro and in vivo testing of current tau PET radiotracers in APs. The tau PET tracers assessed include both first-generation tracers ([18F]AV-1451, [18F]FDDNP, [18F]THK derivatives, and [11C]PBB3) and second-generation tracers ([18F]PM-PBB3, [18F]PI-2620, [18F]RO-948, [18F]JNJ-067, [18F]MK-6240, and [18F]CBD-2115). Concerns regarding off-target binding to cerebral white matter and the basal ganglia are still prominent with first-generation tracers, but this seems to have been mediated in a handful of second-generation tracers, including [18F]PI-2620 and [18F]PM-PBB3. Additionally, these two tracers and [18F]MK-6240 show promising results for imaging PSP- and CBD-tau. Overall, [18F]AV-1451 is the most widely studied tracer but the mixed results regarding its efficacy for use in imaging AP-tau is a cause for concern moving forward. Instead, future work may benefit from focusing on the second-generation radiotracers which seem to have a higher specificity for AP-tau than those originally developed for imaging AD-tau.http://www.sciencedirect.com/science/article/pii/S2590112522000263ParkinsonismPSPCBDParkinson’s diseaseNeuroimagingPET |
| spellingShingle | Anastassia M. Mena Antonio P. Strafella Imaging pathological tau in atypical parkinsonisms: A review Clinical Parkinsonism & Related Disorders Parkinsonism PSP CBD Parkinson’s disease Neuroimaging PET |
| title | Imaging pathological tau in atypical parkinsonisms: A review |
| title_full | Imaging pathological tau in atypical parkinsonisms: A review |
| title_fullStr | Imaging pathological tau in atypical parkinsonisms: A review |
| title_full_unstemmed | Imaging pathological tau in atypical parkinsonisms: A review |
| title_short | Imaging pathological tau in atypical parkinsonisms: A review |
| title_sort | imaging pathological tau in atypical parkinsonisms a review |
| topic | Parkinsonism PSP CBD Parkinson’s disease Neuroimaging PET |
| url | http://www.sciencedirect.com/science/article/pii/S2590112522000263 |
| work_keys_str_mv | AT anastassiammena imagingpathologicaltauinatypicalparkinsonismsareview AT antoniopstrafella imagingpathologicaltauinatypicalparkinsonismsareview |